Essential drugs for cancer therapy: A World Health Organization consultation
Identifieur interne : 00C446 ( Main/Exploration ); précédent : 00C445; suivant : 00C447Essential drugs for cancer therapy: A World Health Organization consultation
Auteurs : K. Sikora [France] ; S. Advani [Inde] ; V. Koroltchouk [France] ; I. Magrath [États-Unis] ; L. Levy [Zimbabwe] ; H. Pinedo [Pays-Bas] ; G. Schwartsmann [Brésil] ; M. Tattersall [Australie] ; S. Yan [République populaire de Chine]Source :
- Annals of Oncology [ 0923-7534 ] ; 1999-04.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme, Médicament générique.
English descriptors
- KwdEn :
Abstract
The WHO has previously produced recommendations on the essential drugs required for cancer therapy. Over the last five years several new anti cancer drugs have been aggressively marketed. Most of these are costly and produce only limited benefits. We have divided currently available anti-cancer drugs into three priority groups. Curable cancers and those cancers where the cost-benefit ratio clearly favours drug treatment can be managed appropriately with regimens based on only 17 drugs. All of these are available, at relatively low cost, as generic preparations. The wide availability of these drugs should be the first priority. The second group of drugs may have some advantages in certain clinical situations. Based on current evidence, drugs in the third group are judged as currently not essential for the effective delivery of cancer care. Adequate supportive care programmes with the widespread availability of effective drugs for pain control are of considerably greater importance. The adoption of these priorities will help to optimise the effectiveness and efficiency of chemotherapy and ensure equitable access to essential drugs especially in low resource environments. Clearly this paper represents the views of its contributors. The WHO welcomes feedback from all oncologists so that the advice it gives to governments in prioritising the procurement of anti cancer drugs can be as comprehensive as possible.
Url:
DOI: 10.1023/A:1008367822016
Affiliations:
- Australie, Brésil, France, Inde, Pays-Bas, République populaire de Chine, Zimbabwe, États-Unis
- Auvergne-Rhône-Alpes, Maryland, Rhône-Alpes
- Lyon
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002492
- to stream Istex, to step Curation: 002492
- to stream Istex, to step Checkpoint: 002108
- to stream Main, to step Merge: 00D419
- to stream PascalFrancis, to step Corpus: 006341
- to stream PascalFrancis, to step Curation: 006D13
- to stream PascalFrancis, to step Checkpoint: 006056
- to stream Main, to step Merge: 00D769
- to stream Main, to step Curation: 00C446
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Essential drugs for cancer therapy: A World Health Organization consultation</title><author><name sortKey="Sikora, K" sort="Sikora, K" uniqKey="Sikora K" first="K." last="Sikora">K. Sikora</name></author><author><name sortKey="Advani, S" sort="Advani, S" uniqKey="Advani S" first="S." last="Advani">S. Advani</name></author><author><name sortKey="Koroltchouk, V" sort="Koroltchouk, V" uniqKey="Koroltchouk V" first="V." last="Koroltchouk">V. Koroltchouk</name></author><author><name sortKey="Magrath, I" sort="Magrath, I" uniqKey="Magrath I" first="I." last="Magrath">I. Magrath</name></author><author><name sortKey="Levy, L" sort="Levy, L" uniqKey="Levy L" first="L." last="Levy">L. Levy</name></author><author><name sortKey="Pinedo, H" sort="Pinedo, H" uniqKey="Pinedo H" first="H." last="Pinedo">H. Pinedo</name></author><author><name sortKey="Schwartsmann, G" sort="Schwartsmann, G" uniqKey="Schwartsmann G" first="G." last="Schwartsmann">G. Schwartsmann</name></author><author><name sortKey="Tattersall, M" sort="Tattersall, M" uniqKey="Tattersall M" first="M." last="Tattersall">M. Tattersall</name></author><author><name sortKey="Yan, S" sort="Yan, S" uniqKey="Yan S" first="S." last="Yan">S. Yan</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C6ED5CC4C0869DDEBC6514D76543BCC3497176DC</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1023/A:1008367822016</idno><idno type="url">https://api.istex.fr/document/C6ED5CC4C0869DDEBC6514D76543BCC3497176DC/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002492</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002492</idno><idno type="wicri:Area/Istex/Curation">002492</idno><idno type="wicri:Area/Istex/Checkpoint">002108</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002108</idno><idno type="wicri:doubleKey">0923-7534:1999:Sikora K:essential:drugs:for</idno><idno type="wicri:Area/Main/Merge">00D419</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:99-0311882</idno><idno type="wicri:Area/PascalFrancis/Corpus">006341</idno><idno type="wicri:Area/PascalFrancis/Curation">006D13</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">006056</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">006056</idno><idno type="wicri:doubleKey">0923-7534:1999:Sikora K:essential:drugs:for</idno><idno type="wicri:Area/Main/Merge">00D769</idno><idno type="wicri:Area/Main/Curation">00C446</idno><idno type="wicri:Area/Main/Exploration">00C446</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Essential drugs for cancer therapy: A World Health Organization consultation</title><author><name sortKey="Sikora, K" sort="Sikora, K" uniqKey="Sikora K" first="K." last="Sikora">K. Sikora</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>WHO Cancer Programme, International Agency for Research on Cancer Lyon</wicri:regionArea><wicri:noRegion>International Agency for Research on Cancer Lyon</wicri:noRegion><wicri:noRegion>International Agency for Research on Cancer Lyon</wicri:noRegion></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Correspondence to: WHO Programme on Cancer Control, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Advani, S" sort="Advani, S" uniqKey="Advani S" first="S." last="Advani">S. Advani</name><affiliation wicri:level="1"><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Medical Oncology Tata Memorial Hospital</wicri:regionArea></affiliation></author><author><name sortKey="Koroltchouk, V" sort="Koroltchouk, V" uniqKey="Koroltchouk V" first="V." last="Koroltchouk">V. Koroltchouk</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>WHO Cancer Programme, International Agency for Research on Cancer Lyon</wicri:regionArea><wicri:noRegion>International Agency for Research on Cancer Lyon</wicri:noRegion><wicri:noRegion>International Agency for Research on Cancer Lyon</wicri:noRegion></affiliation></author><author><name sortKey="Magrath, I" sort="Magrath, I" uniqKey="Magrath I" first="I." last="Magrath">I. Magrath</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Cancer Institute Bethesda, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Levy, L" sort="Levy, L" uniqKey="Levy L" first="L." last="Levy">L. Levy</name><affiliation wicri:level="1"><country xml:lang="fr">Zimbabwe</country><wicri:regionArea>Department of Medicine, University of Zimbabwe Harare</wicri:regionArea><wicri:noRegion>University of Zimbabwe Harare</wicri:noRegion></affiliation></author><author><name sortKey="Pinedo, H" sort="Pinedo, H" uniqKey="Pinedo H" first="H." last="Pinedo">H. Pinedo</name><affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Vrije Universiteit, Department of Medical Oncology Amsterdam</wicri:regionArea><wicri:noRegion>Department of Medical Oncology Amsterdam</wicri:noRegion></affiliation></author><author><name sortKey="Schwartsmann, G" sort="Schwartsmann, G" uniqKey="Schwartsmann G" first="G." last="Schwartsmann">G. Schwartsmann</name><affiliation wicri:level="1"><country xml:lang="fr">Brésil</country><wicri:regionArea>Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul Porto Alegre</wicri:regionArea><wicri:noRegion>Universidade Federal do Rio Grande do Sul Porto Alegre</wicri:noRegion></affiliation></author><author><name sortKey="Tattersall, M" sort="Tattersall, M" uniqKey="Tattersall M" first="M." last="Tattersall">M. Tattersall</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Cancer Medicine</wicri:regionArea></affiliation></author><author><name sortKey="Yan, S" sort="Yan, S" uniqKey="Yan S" first="S." last="Yan">S. Yan</name><affiliation wicri:level="1"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences Beijing</wicri:regionArea><wicri:noRegion>Chinese Academy of Medical Sciences Beijing</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Oncology</title><idno type="ISSN">0923-7534</idno><idno type="eISSN">1569-8041</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="1999-04">1999-04</date><biblScope unit="volume">10</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="385">385</biblScope><biblScope unit="page" to="390">390</biblScope></imprint><idno type="ISSN">0923-7534</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0923-7534</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term><term>Chemotherapy</term><term>Generic drug</term><term>Human</term><term>Malignant tumor</term><term>Treatment</term><term>Treatment efficiency</term><term>WHO</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Anticancéreux</term><term>Chimiothérapie</term><term>Efficacité traitement</term><term>Homme</term><term>Médicament générique</term><term>OMS</term><term>Traitement</term><term>Tumeur maligne</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term><term>Médicament générique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">The WHO has previously produced recommendations on the essential drugs required for cancer therapy. Over the last five years several new anti cancer drugs have been aggressively marketed. Most of these are costly and produce only limited benefits. We have divided currently available anti-cancer drugs into three priority groups. Curable cancers and those cancers where the cost-benefit ratio clearly favours drug treatment can be managed appropriately with regimens based on only 17 drugs. All of these are available, at relatively low cost, as generic preparations. The wide availability of these drugs should be the first priority. The second group of drugs may have some advantages in certain clinical situations. Based on current evidence, drugs in the third group are judged as currently not essential for the effective delivery of cancer care. Adequate supportive care programmes with the widespread availability of effective drugs for pain control are of considerably greater importance. The adoption of these priorities will help to optimise the effectiveness and efficiency of chemotherapy and ensure equitable access to essential drugs especially in low resource environments. Clearly this paper represents the views of its contributors. The WHO welcomes feedback from all oncologists so that the advice it gives to governments in prioritising the procurement of anti cancer drugs can be as comprehensive as possible.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Brésil</li><li>France</li><li>Inde</li><li>Pays-Bas</li><li>République populaire de Chine</li><li>Zimbabwe</li><li>États-Unis</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Maryland</li><li>Rhône-Alpes</li></region><settlement><li>Lyon</li></settlement></list><tree><country name="France"><noRegion><name sortKey="Sikora, K" sort="Sikora, K" uniqKey="Sikora K" first="K." last="Sikora">K. Sikora</name></noRegion><name sortKey="Koroltchouk, V" sort="Koroltchouk, V" uniqKey="Koroltchouk V" first="V." last="Koroltchouk">V. Koroltchouk</name><name sortKey="Sikora, K" sort="Sikora, K" uniqKey="Sikora K" first="K." last="Sikora">K. Sikora</name></country><country name="Inde"><noRegion><name sortKey="Advani, S" sort="Advani, S" uniqKey="Advani S" first="S." last="Advani">S. Advani</name></noRegion></country><country name="États-Unis"><region name="Maryland"><name sortKey="Magrath, I" sort="Magrath, I" uniqKey="Magrath I" first="I." last="Magrath">I. Magrath</name></region></country><country name="Zimbabwe"><noRegion><name sortKey="Levy, L" sort="Levy, L" uniqKey="Levy L" first="L." last="Levy">L. Levy</name></noRegion></country><country name="Pays-Bas"><noRegion><name sortKey="Pinedo, H" sort="Pinedo, H" uniqKey="Pinedo H" first="H." last="Pinedo">H. Pinedo</name></noRegion></country><country name="Brésil"><noRegion><name sortKey="Schwartsmann, G" sort="Schwartsmann, G" uniqKey="Schwartsmann G" first="G." last="Schwartsmann">G. Schwartsmann</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Tattersall, M" sort="Tattersall, M" uniqKey="Tattersall M" first="M." last="Tattersall">M. Tattersall</name></noRegion></country><country name="République populaire de Chine"><noRegion><name sortKey="Yan, S" sort="Yan, S" uniqKey="Yan S" first="S." last="Yan">S. Yan</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00C446 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00C446 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:C6ED5CC4C0869DDEBC6514D76543BCC3497176DC
|texte= Essential drugs for cancer therapy: A World Health Organization consultation
}}
| This area was generated with Dilib version V0.6.33. |  |